This study assessed whether early-adolescent DNA methylation (DNAm) age acceleration predicts later depressive and anxiety symptoms. The investigators combined longitudinal analyses in a London-based adolescent cohort (SCAMP) with two-sample Mendelian randomisation (MR) to triangulate evidence and probe potential causality. The primary finding was an association between PhenoAge acceleration measured at age 11–12 years and higher depressive symptom severity at ages 13–15 years; MR results were consistent with a potential causal relationship.
A subsample of n = 261 adolescents from the SCAMP cohort contributed saliva samples at ages 11–12 years for DNAm profiling. Three established epigenetic clocks were applied to derive measures of age acceleration: Horvath, PhenoAge, and PedBE. Age acceleration represents the extent to which DNAm-estimated biological age exceeds chronological age and is interpreted as an indicator of accelerated biological ageing.
Depressive symptoms were measured at ages 13–15 years using the Patient Health Questionnaire (PHQ). Anxiety symptoms were assessed with the Generalised Anxiety Disorder (GAD) scale. Outcomes included both symptom severity scores and a threshold for clinically significant depressive symptoms.
Logistic regression models tested associations between DNAm age acceleration at 11–12 years and depressive and anxiety outcomes measured at 13–15 years. The main observational results were:
These findings indicate that higher PhenoAge acceleration in early adolescence is linked to increased odds of depressive symptoms two to four years later in this sample.
To assess potential causality, the authors conducted two-sample MR focused on age acceleration estimates from the Horvath and PhenoAge measures and GWAS summary statistics for depression and anxiety. The MR analysis suggested a possible causal effect of PhenoAge acceleration on depression, with the inverse variance weighted (IVW) estimate yielding OR = 1.01 (95% CI 1.00–1.02). Details about instrument strength, sensitivity analyses, and specific MR methods used were reported in the source; the MR result pattern aligned with the longitudinal association observed in the SCAMP cohort.
Across both longitudinal observational and MR analyses, PhenoAge acceleration measured at ages 11–12 years was associated with higher depressive symptoms at ages 13–15 years. The concordance between study designs supports the possibility that PhenoAge acceleration may function as an early biomarker for risk of subsequent depressive symptoms in adolescents. The absence of associations with anxiety outcomes suggests specificity of the observed relationship to depressive symptomatology in this dataset.
Key contextual details reported by the authors include:
Limitations inherent to the reported data include the modest sample size for the DNAm analyses, the use of saliva-derived methylation profiles, and potential residual confounding in observational analyses. The source article provides no additional unreported numeric details beyond the ORs and confidence intervals cited above.
Overall, the study presents convergent longitudinal and genetic-instrument analyses indicating that PhenoAge DNAm age acceleration in early adolescence is associated with increased risk of subsequent depressive symptoms, supporting further investigation of epigenetic ageing markers as early predictors of youth depression.